/wp-content/uploads/iEcure_logo.png00Ellie Solorio/wp-content/uploads/iEcure_logo.pngEllie Solorio2023-03-21 18:54:482023-03-24 17:25:20European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00Ellie Solorio/wp-content/uploads/iEcure_logo.pngEllie Solorio2023-03-15 19:15:252023-03-23 14:57:07iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer
/wp-content/uploads/iEcure_logo.png00Ellie Solorio/wp-content/uploads/iEcure_logo.pngEllie Solorio2022-11-30 00:00:412023-03-24 17:26:58iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-10-19 08:00:312023-03-24 17:28:32Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00Ellie Solorio/wp-content/uploads/iEcure_logo.pngEllie Solorio2022-09-02 20:04:532023-03-24 17:30:23iECURE Receives FDA Orphan Drug Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2022-08-22 19:18:032023-03-24 17:37:04iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-05-25 05:00:362022-05-25 08:00:43iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-05-18 08:00:012022-05-18 08:16:53Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle Disorder to be Presented in Presidential Symposium at ASGCT 2022
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-05-02 19:02:112022-05-10 20:51:39iECURE Announces Presentation of Data on its Gene Editing Approach at the American Society of Cell and Gene Therapy Annual Meeting
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-04-25 07:00:042022-05-10 20:48:21iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders
/wp-content/uploads/iEcure_logo.png00Danielle Cantey/wp-content/uploads/iEcure_logo.pngDanielle Cantey2022-02-01 08:11:062022-02-08 20:32:34iECURE Expands Leadership Team with the Appointment of Mark Semanick as VP and Head of Technical Operations and Brad Dickerson as VP of Project Management & Patient Advocacy
/wp-content/uploads/iEcure_logo.png00Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-12-16 08:00:052022-05-10 20:07:18iECURE Partners to Develop Next-Generation Liver-Targeted Lipid Nanoparticles with University of Pennsylvania
/wp-content/uploads/iEcure_logo.png00Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-12-07 12:29:012022-04-07 21:07:47iECURE Bolsters Senior Management Team with Appointment of David Garrett as Chief Financial Officer
/wp-content/uploads/iEcure_logo.png00Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-09-15 08:00:302022-05-10 20:08:16iECURE Appoints Brian Di Donato to Board of Directors
/wp-content/uploads/iEcure_logo.png00Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-09-15 08:00:072022-05-10 20:08:59iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases
https://iecure.com/wp-content/uploads/insider.svg52280Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-12-01 19:30:422021-12-30 12:41:0634 healthcare and biotech startups that are set to take off in 2022, according to top investors
https://iecure.com/wp-content/uploads/logo-tm.svg52280Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-12-01 19:29:062021-12-29 20:47:04Penn gene editing spinout iECURE just raised a $50M Series A
https://iecure.com/wp-content/uploads/forbes_logo_white.svg50198David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2021-09-09 08:00:322022-02-04 18:51:00This Startup Just Raised $50 Million To Deliver Gene Therapies For Rare Diseases
https://iecure.com/wp-content/uploads/logo-MedCity.svg52280Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-12-01 19:29:522021-12-29 20:44:37Genetic meds pioneer James Wilson has a new startup, this time in gene editing
https://iecure.com/wp-content/uploads/cen-logo.svg52280Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-12-01 19:26:302021-12-29 21:00:35Jim Wilson launches liver disease gene-editing company iECURE with $50 million
https://iecure.com/wp-content/uploads/logo-fiercebiotech.svg52280Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-12-01 19:25:272021-12-29 21:02:46iECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing
https://iecure.com/wp-content/uploads/endpoint-news.svg52280Emily Hennes/wp-content/uploads/iEcure_logo.pngEmily Hennes2021-09-09 08:00:552021-12-30 15:38:36The Tachi Yamada legacy tree continues to grow with a new gene editing biotech from Jim Wilson
https://iecure.com/wp-content/uploads/insider.svg
52
280
Emily Hennes
/wp-content/uploads/iEcure_logo.png
Emily Hennes2021-12-01 19:30:422021-12-30 12:41:0634 healthcare and biotech startups that are set to take off in 2022, according to top investors
https://iecure.com/wp-content/uploads/logo-tm.svg
52
280
Emily Hennes
/wp-content/uploads/iEcure_logo.png
Emily Hennes2021-12-01 19:29:062021-12-29 20:47:04Penn gene editing spinout iECURE just raised a $50M Series A
https://iecure.com/wp-content/uploads/forbes_logo_white.svg
50
198
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2021-09-09 08:00:322022-02-04 18:51:00This Startup Just Raised $50 Million To Deliver Gene Therapies For Rare Diseases
https://iecure.com/wp-content/uploads/logo-MedCity.svg
52
280
Emily Hennes
/wp-content/uploads/iEcure_logo.png
Emily Hennes2021-12-01 19:29:522021-12-29 20:44:37Genetic meds pioneer James Wilson has a new startup, this time in gene editing
https://iecure.com/wp-content/uploads/cen-logo.svg
52
280
Emily Hennes
/wp-content/uploads/iEcure_logo.png
Emily Hennes2021-12-01 19:26:302021-12-29 21:00:35Jim Wilson launches liver disease gene-editing company iECURE with $50 million
https://iecure.com/wp-content/uploads/logo-fiercebiotech.svg
52
280
Emily Hennes
/wp-content/uploads/iEcure_logo.png
Emily Hennes2021-12-01 19:25:272021-12-29 21:02:46iECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing
https://iecure.com/wp-content/uploads/endpoint-news.svg
52
280
Emily Hennes
/wp-content/uploads/iEcure_logo.png
Emily Hennes2021-09-09 08:00:552021-12-30 15:38:36The Tachi Yamada legacy tree continues to grow with a new gene editing biotech from Jim Wilson